Binodenoson is a chemical compound that functions primarily as a selective adenosine A2A receptor agonist. It is characterized by its ability to enhance vasodilation and improve blood flow, making it of interest in cardiovascular research and potential therapeutic applications. The compound is often studied for its effects on the cardiovascular system, particularly in conditions where improved perfusion is desired. Binodenoson is typically administered in a clinical setting, and its pharmacological profile includes a relatively short half-life, which necessitates careful dosing and monitoring. The compound's mechanism of action involves the activation of adenosine receptors, leading to various physiological responses, including relaxation of vascular smooth muscle. As with many pharmacological agents, the safety and efficacy of Binodenoson are evaluated through clinical trials, and it is essential to consider potential side effects and contraindications associated with its use. Overall, Binodenoson represents a significant area of interest in medicinal chemistry and pharmacology, particularly in the context of cardiovascular therapies.

Binodenoson

144348-08-3: Adenosine, 2-[(cyclohexylmethylene)hydrazino]-, SHA 174, 2-[2-(Cyclohexylmethylene)hydrazinyl]adenosine, WRC 0470, Adenosine, 2-[2-(cyclohexylmethylene)hydrazinyl]-

Binodenoson (WRC 0470), a selective A2A adenosine receptor agonist, aids in coronary imaging.

CAS 144348-08-3: Binodenoson

Binodenoson

Ref: 54-BUP03462

Binodenoson

Ref: TM-T9516

Adenosine, 2-[2-(cyclohexylmethylene)hydrazinyl]-

Ref: IN-DA001JDE